Sirona Biochem Renews Agreement with CURE Intelligence for Marketing and Communications Support
VANCOUVER, British Columbia, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona”) is pleased to announce that it has renewed an agreement with Luxembourg-based analytics and marketing specialist CURE Intelligence for marketing intelligence services and communications support.
The agreement has been signed for an additional year of services.
“We have been utilizing the powerful tools provided by CURE Intelligence which keep us informed on relevant market developments and opportunities that relate to our growing pipeline of projects. We have benefited greatly from the intelligence provided to our team members both for scientific and business development opportunities,” said Dr. Howard Verrico, CEO of Sirona Biochem. “We look forward to continuing our relationship with the team at CURE. They have proven their ability to add significant value and improve our communications and market intelligence. We continue to fine-tune these services as we utilize their full potential well beyond communication support.”
"In 2021, Sirona Biochem achieved a very significant milestone with the launch of a commercial product containing a Sirona compound. A great deal of progress was made in business development and scientific research which provides an excellent basis for further positive developments in 2022. We are very much looking forward to continuing to provide Sirona Biochem with relevant market information and contacts, and to raise awareness of the company and its products among investors, partners and the trade press," comments Marco Feiten, Managing Director at CURE Intelligence.
About CURE Intelligence
Founded in 2009, CURE specializes in the field of media monitoring and analysis, data intelligence, social media communications and marketing. CURE helps its clients make better decisions and improve internal and external communication by effectively combining analytics and marketing.
CURE is a public limited company with its headquarters in Grevenmacher, Luxembourg and a subsidiary in Cologne, Germany. CURE works with internationally renowned clients from Germany, Luxembourg, Brazil, Canada and the U.S. For more information, please visit www.cure-intelligence.com.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
For more information regarding this press release, please contact:
Investor Enquiries:
Jonathan Williams
Managing Director
Momentum PR
Canada
Phone: 1.450.332.6939
Email: jwilliams@momentumpr.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
© 2022 GlobeNewswire, Inc. All Rights Reserved.
Attorney General Letitia James Warns New Yorkers to Be Careful of Sham Charities Created in Response to Buffalo Terror Attack
